AbbVie bags major European label expansion for VENCLYXTO in chronic lymphocytic leukemia
The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,
The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,
Strong domestic and international growth, improving product mix, and operational efficiencies drive margin expansion despite exceptional charges impacting quarterly profit
The device screens for conditions like diabetic retinopathy, glaucoma, age-related macular degeneration, cataract and refractive error, in under ten minutes per patient
The syrup launched by company's Chezgreen division is designed to provide supportive care in managing common menstrual concerns such as amenorrhea, dysmenorrhea, and menorrhagia
On a full-year basis, revenue from operations for FY26 grew 18.9 percent year-on-year to Rs 827.87 crore compared to Rs 696.48 crore in FY25
Under the new initiative, each company takes on a defined role across the recycling chain
PAT soars 201%, EBITDA up 88% on strong PHPO demand & margin expansion
For the full year, standalone gross revenue crossed Rs. 1,700 crore
Company launches clinical study of AI-designed oral formulation following MHRA approval, marking a major milestone in AI-driven drug development.
Subscribe To Our Newsletter & Stay Updated